Regencell Bioscience Holdings Ltd
No enriched coverage for $RGC in the last 7 days.
No SEC Form 4 filings for $RGC in the last 30 days.
The article is a press-release style notice in which Rosen and National Trial Lawyers encourage investors to consider legal action related to Regencell Bioscience Holdings. It does not provide specific allegations, financial figures, or case details. The notice directs questions to the company named in the release and states PR-inside is not responsible for the content.
Regencell Bioscience Holdings (NASDAQ:RGC) shares fell 5.1% on Tuesday, trading between $24.30 and $24.48 versus a prior close of $25.80. Volume was 100,662 shares, down 67% from average. Weiss Ratings reiterated a “sell (e+)” rating. The company reported $0.00 EPS in its May 8 quarter.
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and some of its officers, alleging violations of federal securities laws. The lawsuit claims that Regencell made false and misleading statements about the company's operations, business, and compliance policies, leading to market manipulation and significant financial risk for investors. Investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, are encouraged to join the case, with a lead plaintiff deadline of June 23, 2026.
